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Background: Second-generation drug eluting stents (DES) may reduce costs and im-
prove clinical outcomes compared to first-generation DES with improved cost-
effectiveness when compared to bare metal stents (BMS). We aimed to conduct an
economic evaluation of a cobalt-chromium everolimus eluting stent (Co-Cr EES) com-
pared with BMS in percutaneous coronary intervention (PCI). Objective: To conduct
a cost-effectiveness analysis (CEA) of a cobalt-chromium everolimus eluting stent
(Co-Cr EES) versus BMS in PCI. Methods: A Markov state transition model with a
2-year time horizon was applied from a US Medicare setting with patients undergoing
PCI with Co-Cr EES or BMS. Baseline characteristics, treatment effects, and safety
measures were taken from a patient level meta-analysis of 5 RCTs (n5 4,896). The
base-case analysis evaluated stent-related outcomes; a secondary analysis considered
the broader set of outcomes reported in the meta-analysis. Results: The base-case
and secondary analyses reported an additional 0.018 and 0.013 quality-adjusted life
years (QALYs) and cost savings of $236 and $288, respectively with Co-Cr EES versus
BMS. Results were robust to sensitivity analyses and were most sensitive to the price
of clopidogrel. In the probabilistic sensitivity analysis, Co-Cr EES was associated with
a greater than 99% chance of being cost saving or cost effective (at a cost per QALY
threshold of $50,000) versus BMS. Conclusions: Using data from a recent patient level
meta-analysis and contemporary cost data, this analysis found that PCI with Co-Cr
EES is more effective and less costly than PCI with BMS. VC 2016 The Authors. Catheterization
and Cardiovascular Interventions Published by Wiley Periodicals, Inc.
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INTRODUCTION
As the first major drug-device combination product
for cardiovascular disease, drug-eluting stents (DES)
represented a clinical breakthrough in treatment of
patients with coronary artery disease (CAD) [1]. The
technology continues to evolve, with the recent devel-
opment of second-generation DES platforms such as
the cobalt chromium (Co-Cr) everolimus-eluting stent
(EES). These platforms are comprised of permanent
polymer coatings, less toxic antiproliferative drugs
(e.g., everolimus or zotarolimus), and thin strut stent
designs compared with first-generation DES.
Robust randomized controlled trials (RCTs) and sev-
eral meta-analyses of RCTs have shown that Co-Cr
EES is significantly safer and more effective than bare
metal stents (BMS), with lower rates of stent thrombo-
sis (ST), myocardial infarction (MI), and cardiac mor-
tality [2–8]. A recent patient level meta-analysis of
4,896 patients from five RCTs (including three all
comer studies) found that patients receiving Co-Cr
EES had significant reductions in cardiac mortality,
MI, definite ST, definite or probable ST, and target
vessel revascularization (TVR) versus patients receiv-
ing BMS [5]. There are also some indications that
second-generation DES reduce costs and improve clini-
cal outcomes compared to first-generation DES [9],
with improved cost-effectiveness versus BMS [10–12].
The current study leverages the availability of data
from the patient level meta-analysis of RCTs to ad-
dress the cost effectiveness of Co-Cr EES compared to
BMS.
METHODS
Type of Analysis and Perspective. The cost-
effectiveness analysis (CEA) was conducted for a
2-year time horizon from the US Medicare perspective
[13]. A 2-year time horizon was selected to align with
the patient level meta-analysis [5] and previous cost-
effectiveness studies of DES compared to BMS
[10,14–17]. Costs and outcomes at year 2 were dis-
counted at a rate of 3%.
Study Population
The mean age of patients included in the patient lev-
el meta-analysis was 67 years and the majority of
patients included were male (76%). Type 2 diabetes
mellitus was present in approximately 19% of patients.
Forty-four percent of all patients received stenting in
the setting of primary PCI and more than 87% under-
went PCI treatment for an unstable presentation. The
methods and results of the meta-analysis have been
reported in detail by Valgimigli et al. [5].
Model Overview
A Markov state transition model was developed in
Microsoft Excel 2007 using effectiveness and safety
data from the patient level meta-analysis (Fig. 1) [5].
Patients started the model in the “alive” health state,
and during each model cycle of 1 year, could transition
to deceased. During each 1-year model cycle, “event-
free” patients could also experience one or more of the
following transient events: MI, ST or TVR. Event risks
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were only available to inform the probability of mov-
ing from event-free to a transient event; data was not
available to inform movement between the transient
events. The data inputs used in the CEA are summa-
rized in Table I.
Transition Probabilities and Event Risks
The risks of mortality, MI, ST, and TVR were in-
formed by the patient level meta-analysis [5]. The
authors of the meta-analysis provided the number of
patients at risk and the number of events for each treat-
ment group, stratified by year 1 and year 2. The
authors also provided cause of mortality (i.e., all-cause
or cardiac-related) and type of MI (i.e., TVR-related,
any MI).
Resource Use and Unit Costs
The focus of the CEA was costs borne by the US
Medicare program, including costs associated with the
percutaneous coronary intervention (PCI) procedure
(including the stent), TVR, MI, and dual antiplatelet
therapy (DAPT). Estimates of resource use and unit
costs (2015 US dollars) were obtained from the pub-
lished literature. Additional technology costs associated
with DES versus BMS were included in diagnosis-
related group (DRG) payments.
For patients who experienced TVR, re-intervention
could be performed by means of coronary artery by-
pass graft (CABG) or PCI (with stent or without stent).
The proportions of patients receiving CABG (10%) or
PCI (90%) were taken from a publication reported by
Garg et al. [18]. The breakdown of re-intervention with
PCI was assumed to be PCI with DES (56%) and PCI
without stent (44%) [18].
In the patient level meta-analysis, the duration of
DAPT (i.e., clopidogrel in addition to aspirin) ranged
from 3 months to 24 months for both DES and BMS
[5]. The European Society of Cardiology (ESC) guide-
lines recommend a DAPT duration of at least 1 month
for BMS and 6 months for DES [19]. The ACC guide-
lines recommended a DAPT duration of 1 month for
BMS and 12 months for DES [20]. For the base-case
analysis, we assumed a DAPT duration of 6 months
for BMS and 12 months for DES. Generic pricing of
clopidogrel (75 mg) was based on the wholesale acqui-
sition cost (WAC) published in the US Redbook online
pricing database [21]. A 20% mark-up was added to
the WAC to be more conservative and to arrive at a to-
tal monthly acquisition cost of $23.64 that more close-
ly reflected the average wholesale price (AWP) [22].
An alternative monthly DAPT cost of $91.82 (assum-
ing 50% generic and 50% brand clopidogrel) was eval-
uated in the sensitivity analyses.
Health Utility
Quality of life impacts were included for CAD, MI,
and TVR. A health utility value of 0.85 was applied in
the model to patients with CAD and no symptoms [18].
For patients experiencing TVR a health utility decrement
of 0.06 was applied for 1 year following the re-
intervention, irrespective of revascularization with CABG
or PCI [18]. For patients experiencing MI, a health utility
of 0.75 was applied for 1 year following the MI [18].
Analysis
The base-case analysis included clinical outcomes
from the patient level meta-analysis that were consid-
ered to be stent-related: TVR, TVR-related MI, definite
ST, and cardiac-related mortality. A secondary analysis
was conducted that considered the broader set of clini-
cal outcomes from the meta-analysis: TVR, all MI,
definite ST, and all-cause mortality.
One-way sensitivity analyses were conducted in or-
der to test the robustness of the base-case analysis to
alternative assumptions and data inputs related to tran-
sition probabilities, risks of events, resource use,
DAPT therapy costs, and health utility (Table II)
[20,23–25]. A probabilistic sensitivity analysis (PSA)
was conducted to simultaneously quantify the uncer-
tainty in all key model input parameters.
RESULTS
Base-Case Analysis
Results of the base-case analysis (Table III) demon-
strated that Co-Cr EES was more efficacious than
BMS. Patients who received PCI with Co-Cr EES ex-
perienced fewer cardiac-related deaths, TVR-related
MIs, ST, and TVRs, 0.015 additional life years, and
0.018 additional QALYs compared with patients who
received PCI with BMS. PCI with Co-Cr EES was also
associated with cost savings of $236 per patient. The
primary drivers of the cost savings were the reduction
in TVR and MI rates, which offset the increased costs
Fig. 1. Overview of the model structure. The model captured
both base-case (i.e., TVR, TVR-related MI, ST, and cardiac
mortality) and secondary analysis (i.e., TVR, MI, ST, all-cause
death) outcomes. MI5myocardial infarction; ST5stent
thrombosis; TVR5 target vessel revascularization.
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TABLE I. Summary of Model Parameters for the Base-Case and Secondary Analyses
Input parameter Intervention Sources
Event risks (%) (years 0–2) Co-Cr EES BMS
All-cause mortalitya 4.9 5.9 Valgimigli et al. [5]
Cardiac-related mortalityb 2.7 4.1
TVRa,b 4.3 10.2
Any MIa 4.0 5.6
TVR-related MIb 0.9 1.8
Definite STa,b 0.6 1.4
Procedure proportions Both interventions
PCI with DES Medicare claims data [34]
Inpatient (index procedure) 64%
Outpatient (index procedure) 36%
Inpatient with MCC; w/o CC or MCC 18%; 82% HCUPnet [35]
Outpatient with AMI or CTO; w/o AMI or CTO 5%; 95%
PCI with BMS Medicare claims data [34]
Inpatient (index procedure) 64%
Outpatient (index procedure) 36%
Inpatient with MCC; w/o CC or MCC 25%; 75% HCUPnet [35]
Outpatient with atherectomy; w/o atherectomy 0%; 100%
Unit costs (USD) Both Interventions
Procedure reimbursement [36,37] References 36,37
PCI with DES
Inpatient with MCC; w/o CC or MCC $19,009 DRG 246
Inpatient w/o CC or MCC $12,090 DRG 247
Outpatient with AMI or CTO $14, 841 APC 319
Outpatient w/o AMI or CTO $9,624 APC 229
PCI with BMS
Inpatient with MCC $17,860 DRG 248
Inpatient w/o CC or MCC $11,046 DRG 249
Outpatient with atherectomy $14,841 APC 319
Outpatient w/o atherectomy $9,624 APC 229
PCI (no stent)
Inpatient with MCC $17,551 DRG 250
Inpatient w/o CC or MCC $11,980 DRG 251
Outpatient with PTA $4,537 APC 083
Outpatient w/o PTA –
CABG [36], Inpatient market estimator, unpublished data, 2015 $30,669 DRG 231–236c
Event costs
MI [35,36] $7,814 DRG 231–236d
TVR-Treated with CABG See above
TVR-Treated with PCI DES See above
TVR-Treated with PCI no Stent See above
DAPT costs and duration
Generic clopidogrel (75 mg) monthly cost [21] $23.64
Brand clopidogrel (75 mg) monthly cost [23] $160.00
Clopidogrel duration–Co-Cr EES [5] 12 months
Clopidogrel duration–BMS [5] 6 months
Health Utilities [18] Both Interventions
CAD (no symptoms) 0.85
TVR
PCI (0–6, 6–12 months) 0.79
CABG (0–6, 6–12 months) 0.79
MI (12 months) 0.75
aVariables used in base-case analysis.
bVariables used in secondary analysis.
cProcedure weights based on Cardiovascular Inpatient Market Estimator.
dProcedure weights based on HCUPnet.
AMI¼ acute myocardial infarction; APC¼ ambulatory patient classification; CABG¼ coronary artery bypass graft; CC¼ complications or comorbid-
ities; CTO¼ chronic total occlusion; CV¼ cardiovascular; DAPT¼ dual antiplatelet therapy; DES¼ drug eluting stent; DRG¼ diagnosis-related
group; HCUP¼Healthcare Cost Utilization Project; MCC¼major complications or comorbidities; MI¼myocardial infarction; PCI¼ percutaneous
coronary intervention; PTA¼ percutaneous transluminal angioplasty; ST¼ stent thrombosis; TVR¼ target vessel revascularization; USD¼United
States dollars; w¼with; w/o¼without.
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of the index procedure and DAPT observed with Co-
Cr EES versus BMS.
Results of the secondary analysis (not shown) dem-
onstrated similar results to the base-case analysis. PCI
with Co-Cr EES was both more effective (0.009 addi-
tional life years and 0.013 additional QALYs per pa-
tient) and less costly (-$288 per patient) versus BMS.
One-Way Sensitivity Analysis
The base-case results were robust to a number of sensi-
tivity analyses. When inputs were varied by 20%,
results remained cost savings for Co-Cr EES relative to
BMS in all cases (not shown). Similarly, when base-case
inputs were varied using alternative values taken from
published literature [20,23–25], all analyses showed that
TABLE II. Summary of Model Inputs for Additional One-Way Sensitivity Analyses
Input parameter
Base-case value(s) Alternative value(s)
Co-Cr EES BMS Co-Cr EES BMS
DAPT duration
Turco 2012 [23] 12 months 6 months 12 months 12 months
2011 ACC/AHA/SCAI guidelines for PCI [20] 12 months 1 month
2014 ESC/EACTS guidelines on revascularization [30] 6 months 1 month
Clopidogrel cost (50% generic & 50% brand price) $23.64 $91.82
Cost of MI
Patient receiving CABG [25] $7,814 $9,344
Patient receiving PCI [25] $6,230
Health utility for MI [24] 0.75 0.72
Health utility for TVR (0–6 months, 6–12 months) [24] 0.79 0.75
TVR procedure (%)a CABG¼ 10; PCI¼ 90 CABG¼ 13.2; PCI¼ 86.8
aBased on unpublished 2012 data from HCUP.net and MEDPAR data.
ACC¼American College of Cardiology; AHA¼American Heart Association; CABG¼ coronary artery bypass graft; DAPT¼ dual antiplatelet thera-
py; EACTS¼European Association for Cardio-Thoracic Surgery; ESC¼European Society of Cardiology; HCUP¼Healthcare Cost Utilization Pro-
ject; MI¼myocardial infarction; PCI¼ percutaneous coronary intervention; SCAI ¼Society Cardiovascular Angiography Interventions; TVR¼ target
vessel revascularization.
TABLE III. Model Predicted Results for Base-Case (A) and Secondary (B) Analyses
Outcome Co-Cr EES BMS Difference (Co-Cr EES-BMS)
(A) Base-case analysis
Cardiac-related deaths* 27 41 14
TVR-related MI* 9 18 9
Definite stent thrombosis* 6 14 8
TVR* 43 102 59
Life years per patient 1.935 1.920 0.015
QALYs/patient 1.642 1.624 0.018
Total costs (USD)* $12,999,798 $13,235,578 -$235,780
Index procedure* $12,093,215 $11,624,320 $468,895
TVR* $553,758 $1,329,344 -$775,586
MI* $69,145 $140,074 -$70,929
DAPT* $283,680 $141,840 $141,840
(B) Secondary analysis
All-cause deaths* 49 59 10
Any MI* 40 56 16
Definite stent thrombosis* 6 14 8
TVR* 43 102 60
Life years per patient 1.909 1.900 0.009
QALYs/patient 1.616 1.603 0.013
Total costs (USD)* $13,237,583 $13,525,567 -$287,984
Index procedure* $12,093,215 $11,624,320 $468,895
TVR* $551,574 $1,327,315 -$775,741
MI* $309,114 $432,092 -$122,978
DAPTa $283,680 $141,840 $141,840
aPer cohort of 1,000 patients; model predicted clinical outcome results differ slightly from clinical results reported in the Valgimigli 2014 meta-
analysis due to model calculation and rounding requirements.
DAPT¼ dual antiplatelet therapy; MI¼myocardial infarction; QALYs¼ quality-adjusted life years; TVR¼ target vessel revascularization; USD¼
United States dollars.
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Co-Cr EES was more effective and less costly versus
BMS, with the exception of the cost of clopidogrel, which
resulted in a cost of $9,755 per QALY gained (Table IV).
Probabilistic Sensitivity Analysis
Figure 2 depicts the results of the PSA on the cost-
effectiveness scatter plot for the base-case analysis (A)
and the secondary analysis (B). Each point on each
scatterplot represents the incremental QALYs for Co-
Cr EES versus BMS (x-axis) and the incremental cost
of Co-Cr EES versus BMS (y-axis) for each of the
TABLE IV. Results of Sensitivity Analyses Using Alternative Published Values, Reported for the Base-Case Analysis Only
Analysis description
Incremental
cost (USD)
Incremental
QALY
Cost per QALY
gained (USD)
Base-case analysis $235.78 0.0178 Cost savings
TVR procedures (CABG: 13.2%, PCI: 86.8%) $272.77 0.0178 Cost savings
DAPT duration (Co-Cr EES: 12 months, BMS: 12 months) $377.62 0.0178 Cost savings
DAPT duration (Co-Cr EES: 12 months, BMS: 1 month) $117.58 0.0178 Cost savings
DAPT duration (Co-Cr EES: 6 months, BMS: 1 month) $259.42 0.0178 Cost savings
Clopidogrel cost (50% generic; 50% brand) $173.30 0.0178 $9,754.88
Cost of MI (CABG patients) $249.67 0.0178 Cost savings
Cost of MI (PCI patients) $221.40 0.0178 Cost savings
Utility for MI (0.72) $235.78 0.0180 Cost savings
Utility for PCI; 0–6, 6–12 (0.75) $235.78 0.0199 Cost savings
CABG¼ coronary artery bypass graft; DAPT¼ dual antiplatelet therapy; MI¼myocardial infarction; PCI¼ percutaneous coronary intervention;
TVR¼ target vessel revascularization; QALY¼ quality-adjusted life year; USD¼United States dollars.
Fig. 2. Results of the probabilistic sensitivity analysis on the
cost-effectiveness scatter plot for the base-case analysis (A)
and the secondary analysis (B) [28]. QALY5quality-adjusted
life year; USD5United States dollars.
Fig. 3. Results of the probabilistic sensitivity analysis using
cost-effectiveness acceptability curves for the base-case
analysis (A) and the secondary analysis (B) [28]. BMS5bare-
metal stent; Co-Cr EES5cobalt chromium everolimus-eluting
stent; USD5United States dollars.
6 Ferko et al.
Catheterization and Cardiovascular Interventions DOI 10.1002/ccd.
Published on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
1,000 model simulations [26,27]. For the base-case
analysis, 88.5% of the model iterations showed Co-Cr
EES to be cost savings versus BMS. In 10.6% of the
model iterations, Co-Cr EES was more effective and
more costly than PCI with BMS. In the remaining
model iterations, Co-Cr EES was less effective [28].
Very similar results were observed for the secondary
analysis; Co-Cr EES was cost savings versus BMS in
91.1% of the model iterations and Co-Cr EES was
more effective and more costly than BMS in 5.8% of
the model iterations.
Figure 3 shows the CEACs for both the base-case
and secondary analyses. At willingness-to-pay (WTP)
thresholds of $50,000 per QALY, the base-case PSA
predicted that Co-Cr EES was associated with a 99.5%
likelihood of being cost-savings or cost effective. For
the secondary analysis, the PSA predicted that Co-Cr
EES was associated with a 99.2% likelihood of being
cost-savings or cost effective.
DISCUSSION
Statement of Principal Findings
This 2-year CEA found that PCI with Co-Cr EES is
more effective and less costly compared with PCI with
BMS in contemporary US clinical practice. The base-
case analysis found that a patient who received Co-Cr
EES experienced an additional 0.018 QALYs and cost
savings of $236 compared with a patient who received a
BMS. The findings were consistent between the base-
case analysis and the secondary analysis that included
broader outcomes.
Strengths and Limitations
The evaluation was based on a patient level meta-
analysis of RCTs, a research methodology that is widely
regarded as the highest level of evidence and has inherent
advantages over individual RCTs and aggregate data
meta-analyses [29–31]. Furthermore, the patient popula-
tion of the RCTs included in the meta-analysis is general-
ly reflective of real-world clinical practice. This analysis
was also based on several conservative assumptions, in-
cluding a short-term time horizon and the assumption
that a high proportion of re-interventions employed an-
gioplasty only [32]. Finally, the results of our analyses
were robust across a range of sensitivity analyses.
Uncertainty remains regarding the appropriate dura-
tion of DAPT for patients receiving Co-Cr EES. A re-
cent meta-analysis of 10 RCTs of DES showed that
patients using DAPT for less than 12 months showed
lower risk of major bleeding with no significant in-
crease in thrombotic outcomes compared with patients
using DAPT for 12 months [33]. A 12-month duration
of DAPT for Co-Cr EES was assumed for the base-
case analysis, and the results were found to be robust
to a wide range of alternative assumptions. However,
care should be exercised when generalizing the results
of the economic evaluation to environments in which
practice patterns, resource utilization, and costs differ
from those assumed in this analysis.
Comparison With Other Studies
To our knowledge, this CEA is the first to find that
Co-Cr EES is economically dominant versus BMS.
Cost savings were driven primarily by significant
reductions in MI, ST, and cardiac mortality with Co-Cr
EES relative to BMS. Other key drivers of the analysis
include the declining price differential between DES
and BMS and the availability of generic clopidogrel.
Other recent economic evaluations have reported
conflicting results regarding the economic value of
DES. In 2010, Remak et al. [11] reported a CEA of
patients treated with the Endeavor DES or BMS over 4
years and reported a low cost per QALY of £3,575.
Like our analysis, Remak et al. incorporated a reduc-
tion in the risk of MI and death for DES, a smaller
price difference between DES and BMS (£500), and
relatively low cost of generic clopidogrel (£35 per
month). It is noteworthy that the magnitude of the clin-
ical benefit at 2 years was reported to be lower in the
Remak study compared to the current study; however
the Remak data extended to 4 years. Schafer et al. [10]
reported an economic evaluation of first-generation
DES using 3-year, real-world, observational data from
the US and reported a high cost per QALY of $87,705
for DES versus BMS. Importantly, Schafer and col-
leagues did not incorporate a reduction in the risk of
MI for DES and assumed a relatively high cost of clo-
pidogrel (i.e., $140 per month). The authors noted that
lower generic clopidogrel and DES costs would result
in overall cost-savings for DES versus BMS.
In contrast, Barone-Rochette et al. [12] reported that
DES was not cost-effective (i.e., at a WTP threshold of
e10,000 per revascularization avoided) at a price dif-
ferential of e1,200 (e2,008), but that it became cost ef-
fective at a price differential of e400 (e2,012). No
differences in MI, ST, or cardiac mortality were mod-
eled in this analysis. Finally, a 2013 economic evalua-
tion based on Canadian observational data for patients
with stable coronary disease also questioned the cost
effectiveness of DES and recommended broad use of
BMS [24]. However, the observational data were based
on patients receiving first-generation stents from 2003
to 2005 and the unit costs of DES vs. BMS (i.e.,
$2,519 vs. $657, respectively) used in the analysis
were also presumably from that timeframe.
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Impact on Daily Practice
The findings of this study hold practical importance
for payers, policymakers and clinicians evaluating the
clinical and economic value of Co-Cr EES and other
cardiovascular innovations. As PCI technology and clin-
ical practice rapidly advanced from first-generation DES
to Co-Cr EES, it has represented a “moving target” that
underscores the importance of updating health technolo-
gy assessment (HTA) and economic evaluations to re-
flect changes in economic value over time. In contrast
to early analyses involving first-generation DES, our
economic analysis based on the highest level of clinical
evidence finds that PCI with Co-Cr EES is more effec-
tive and less costly than PCI with BMS in contemporary
US clinical practice.
CONCLUSIONS
Studies assessing the cost effectiveness of DES ver-
sus BMS have reported mixed results due to multiple
factors including limitations of first-generation DES.
Utilizing the latest data from the US Medicare program
and clinical results from a high-quality, patient level
meta-analysis of RCTs our study finds that Co-Cr EES
is an economically attractive strategy compared with
BMS in patients undergoing PCI.
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